outcome assessment

Vitamin K and osteoarthritis: is there a link?
Richard F Loeser, Francis Berenbaum, Margreet Kloppenburg

Annals of the Rheumatic Diseases May 2021, 80 (5) 547-549; DOI: 10.1136/annrheumdis-2020-219765
New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis
Dinesh Khanna, Suiyuan Huang, Celia J F Lin, Cathie Spino

Annals of the Rheumatic Diseases May 2021, 80 (5) 641-650; DOI: 10.1136/annrheumdis-2020-219100
Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic
Naomi Serling-Boyd, Kristin M D’Silva, Tiffany YT Hsu, Rachel Wallwork, Xiaoqing Fu, Ellen M Gravallese, April M Jorge, Yuqing Zhang, Hyon Choi, Jeffrey A Sparks, Zachary S Wallace

Annals of the Rheumatic Diseases May 2021, 80 (5) 660-666; DOI: 10.1136/annrheumdis-2020-219279
Realising early recognition of arthritis in times of increased telemedicine: the value of patient-reported swollen joints
Cleo Rogier, Bastiaan T van Dijk, Elisabeth Brouwer, Pascal H P de Jong, Annette H M van der Helm-van Mil

Annals of the Rheumatic Diseases May 2021, 80 (5) 668-669; DOI: 10.1136/annrheumdis-2020-219513
Declining in-hospital mortality gap between systemic lupus erythematosus (SLE) and non-SLE hospitalisations: a national study
Jasvinder A Singh, John D Cleveland

Annals of the Rheumatic Diseases May 2021, 80 (5) 672-675; DOI: 10.1136/annrheumdis-2020-218386
Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020
Wenhui Xie, Hong Huang, Guangtao Li, Yanjie Hao, Yanni Gui, Yu Wang, Xuerong Deng, Juan Zhao, Yan Geng, LanLan Ji, Xiaohui Zhang, Zhibo Song, Zhuoli Zhang

Annals of the Rheumatic Diseases Apr 2021, annrheumdis-2021-220112; DOI: 10.1136/annrheumdis-2021-220112
Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial
Veerle Stouten, René Westhovens, Sofia Pazmino, Diederik De Cock, Kristien Van der Elst, Johan Joly, Delphine Bertrand, Patrick Verschueren

Annals of the Rheumatic Diseases Apr 2021, annrheumdis-2020-219825; DOI: 10.1136/annrheumdis-2020-219825
Correspondence on ‘Statistical review: frequently given comments’
Daisuke Waki, Masahiro Banno, Takashi Fujiwara

Annals of the Rheumatic Diseases Mar 2021, annrheumdis-2021-220332; DOI: 10.1136/annrheumdis-2021-220332
Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised controlled trial’
Liseth de Wolff, Suzanne Arends, Gwenny M Verstappen, Arjan Vissink, Frans G M Kroese, Hendrika Bootsma

Annals of the Rheumatic Diseases Mar 2021, annrheumdis-2021-220198; DOI: 10.1136/annrheumdis-2021-220198
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
Roy M Fleischmann, Ricardo Blanco, Stephen Hall, Glen T D Thomson, Filip E Van den Bosch, Cristiano Zerbini, Louis Bessette, Jeffrey Enejosa, Yihan Li, Yanna Song, Ryan DeMasi, In-Ho Song

Annals of the Rheumatic Diseases Apr 2021, 80 (4) 432-439; DOI: 10.1136/annrheumdis-2020-218412

Main menu

outcome assessment

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

outcome assessment

Pages